RAYMOND JAMES & ASSOCIATES - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$249,677
-58.7%
24,745
-8.3%
0.00%
-100.0%
Q3 2022$605,000
-18.1%
26,984
-9.5%
0.00%0.0%
Q2 2022$739,000
-35.2%
29,815
+1.3%
0.00%0.0%
Q1 2022$1,141,000
-5.5%
29,436
+42.6%
0.00%0.0%
Q4 2021$1,208,000
-0.1%
20,646
+1.2%
0.00%0.0%
Q3 2021$1,209,000
-30.5%
20,396
+1.8%
0.00%
-50.0%
Q2 2021$1,739,000
+5.3%
20,041
+0.1%
0.00%0.0%
Q1 2021$1,651,000
-20.9%
20,025
-12.8%
0.00%0.0%
Q4 2020$2,088,000
+155.9%
22,959
+12.4%
0.00%
+100.0%
Q3 2020$816,000
+11.3%
20,425
-4.3%
0.00%0.0%
Q2 2020$733,000
+48.4%
21,350
-4.0%
0.00%0.0%
Q1 2020$494,000
-26.3%
22,250
-35.0%
0.00%0.0%
Q4 2019$670,000
+6.7%
34,247
-15.3%
0.00%0.0%
Q3 2019$628,000
-10.7%
40,457
+16.8%
0.00%0.0%
Q2 2019$703,000
+22.9%
34,638
+6.4%
0.00%0.0%
Q1 2019$572,000
+62.5%
32,548
+18.6%
0.00%0.0%
Q4 2018$352,000
-26.2%
27,438
-6.3%
0.00%0.0%
Q3 2018$477,000
+54.9%
29,288
+7.7%
0.00%0.0%
Q2 2018$308,000
+18.0%
27,203
+1.7%
0.00%
Q1 2018$261,000
+85.1%
26,750
+16.2%
0.00%
Q4 2017$141,00023,0250.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 3,379,064$34,0959.92%
Redmile Group, LLC 12,957,222$130,738,3705.35%
GCM Grosvenor Holdings, LLC 1,037,256$10,465,9132.67%
Casdin Capital, LLC 2,050,000$20,684,5001.60%
DAFNA Capital Management LLC 550,940$5,558,9851.57%
Artal Group S.A. 2,600,000$26,2341.46%
Monaco Asset Management SAM 250,000$2,522,5000.76%
Parametrica Management Ltd 32,254$325,4430.67%
Boxer Capital, LLC 1,250,000$12,612,5000.66%
Bellevue Group AG 4,861,279$49,050,3050.65%
View complete list of FATE THERAPEUTICS INC shareholders